Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?
In the setting of the recent TailorRx data, would these patients be considered more high risk?
Answer from: Medical Oncologist at Academic Institution
The TAILORx trial showed that endocrine therapy was noninferior to chemoendocrine therapy in the primary endpoint of invasive-disease free survival among patients who had a recurrence score between 11-25. However, an exploratory subgroup analysis showed a significant interaction between chemotherapy...
Sign in or Register to read more